Heterogeneity of the resistance to gefitinib treatment in a non-small cell lung cancer patient with active epidermal growth factor receptor mutation

Chong-Rui Xu, Wen-Zhao Zhong, Qing Zhou, Xu-Chao Zhang, Jin-Ji Yang & Yi-Long Wu

Division of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China

Keywords
EGFR; heterogeneity; lung cancer; TKI.

Correspondence
Yi-Long Wu, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Medical Research Center, 106 Zhongshan 2nd Road, 510080 Guangzhou, China.
Tel: +86 20 8387 7557
Fax: +86 20 8384 4620
Email: syylwu@live.cn

Received: 11 May 2016;
Accepted: 28 June 2016.
doi: 10.1111/1759-7714.12382

Thoracic Cancer 8 (2017) 51–53

Abstract
We report the case of a 37-year-old male non-small cell lung cancer patient with an active epidermal growth factor receptor (EGFR) mutation who received gefitinib as first-line treatment. After 13.7 months, the patient experienced disease progression and was treated with platinum-based doublet chemotherapy plus gefitinib for 5.4 months. A subsequent lung biopsy showed cMET overexpression; therefore, the patient received a cMET inhibitor with the gefitinib. The response in the different lesions of several organs was diverse. Stable disease was achieved in the lung lesion; however, the liver metastases enlarged. A liver biopsy found T790M mutation in EGFR exon 20, thus, third generation EGFR-tyrosine kinase inhibitors were used and a partial response was achieved.

Introduction
In advanced non-small cell lung cancer (NSCLC) patients, the median overall survival (OS) with platinum-based doublet chemotherapy is less than a year. The introduction of target drugs, such as gefitinib, erlotinib, afatinib, and crizotinib has achieved survival rates of more than two years in NSCLC patients with driver gene mutations. Beyond progression there is still chance for patients to received targeted treatment, which is determined according to the resistance mechanism.

Case report
A 37-year-old male patient presented to our hospital complaining of a cough that had lasted two months. The patient had never smoked and had no family history of cancer. His Eastern Cooperative Oncology Group performance status (PS) score was 1. The right supraclavicular lymph node could be touched during the physical examination. Positron-emission tomography-computed tomography (PET/CT) taken on 11 September 2012 showed right lower lung cancer with multiple metastases to the bilateral lung, right supraclavicular lymph node, and liver metastases. A biopsy of the lymph node taken on 15 September 2012 determined adenocarcinoma with an epidermal growth factor receptor (EGFR) exon 19 mutation, detected by the real time-polymerase chain reaction (RT-PCR). The diagnosis was cT4N3M1a (lung) stage IV right lower lung adenocarcinoma.

From 26 September 2012 the patient received gefitinib and achieved a partial response (PR). A CT scan taken on 8 November 2013 confirmed progressive disease (PD). The progression-free survival (PFS) rate was 13.7 months. He was enrolled in the IMPRESS trial and received six cycles of pemetrexed/cisplatinum chemotherapy with gefitinib from 20 November 2013. Stable disease (SD) was initially achieved; however, PD was confirmed on 3 May 2014 with PFS of 5.4 months. The second biopsy from the primary lesion in the lung taken on 20 May 2014 showed...
adenocarcinoma with EGFR exon 19 mutation but no exon 20 mutation, detected by RT-PCR. Mesenchymal epithelial transition (MET) immunohistochemistry (IHC) was positive (Fig 1) and fluorescence in situ hybridization (FISH) was negative. The patient was enrolled in a clinical trial and treated with cMET inhibitor INC280 plus gefitinib from 12 June 2014. SD was achieved. On 7 October 2014, the primary lesion in the lung was reduced, while a new lesion appeared in the liver (Fig 2). The PFS was 3.8 months. A biopsy of the liver tumor was performed on 20 October 2014, which confirmed that the adenocarcinoma had metastasized from the lung, with EGFR exon 20 T790M mutation detected by RT-PCR. IHC and FISH of cMET were negative. From 5 January 2015, the patient was enrolled in a third generation EGFR-tyrosine kinase inhibitor (TKI) trial (NCT02330367) and was treated with avitinib (AC0010). The patient achieved PR.

**Discussion**

In the past, the standard treatment for advanced NSCLC patients has been first-line platinum-based doublet chemotherapy and second-line chemotherapy. After the introduction of EGFR-TKIs for NSCLC, patients with EGFR positive mutation have benefitted from longer PFS than with chemotherapy. After the progression of the first-line EGFR-TKIs, doublet chemotherapy became the standard treatment, presenting an opportunity at subsequent biopsy to determine the resistance mechanism. The major resistance mechanism was related to the secondary mutation (T790M) of the EGFR gene at exon 20. Another mechanism was cMET alteration, including overexpression, amplification, or mutation. The cMET inhibitor and the third generation EGFR-TKIs focused on T790M were developed to solve the problem of resistance.

The patient in this case received gefitinib as first-line treatment and achieved PFS of 13.7 months. After progression, he received platinum doublet chemotherapy, with PFS of 5.4 months. A subsequent lung biopsy showed cMET overexpression. After the patient was administered the cMET-inhibitor, a different response was observed between the lung lesion and the liver metastases. A liver biopsy confirmed heterogeneity between the two sites. A T790M mutation of EGFR exon 20 was found in the liver metastases, which was not found in the lung lesion. The patient received third generation EGFR-TKIs focused on the T790M mutation and achieved PR. He received different target therapy drugs according to the gene alteration
during different periods, including gefitinib for the EGFR active mutation, cMET inhibitor for the cMET overexpression, and third-generation EGFR-TKIs for the T790M mutation. The heterogeneity of the tumor was another consideration after the progression of target therapy. A different strategy was required to deal with the different responses to treatment. The subsequent biopsy was helpful to determine the reason for the resistance. After targeted treatment, the patient has now survived more than three years.

In conclusion, we report a case of heterogeneity in the resistance to EGFR-TKI. A subsequent biopsy can determine the different mechanisms of different tumor locations, and then targeted treatment toward the driver gene alteration can be administered.

Acknowledgments
We thank the patient participated in our research and all the doctors including pathologist Li-Xu Yan who perform the examination and treatment for the patient.

Disclosure
No authors report any conflict of interest.

References
1 Yang JC, Wu YL, Schuler M et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncology 2015; 16: 141–51.
2 Tan CS, Gilligan D, Pacey S. Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. Lancet Oncology 2015; 16: e447–59.
3 Soria JC, Wu YL, Nakagawa K et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): A phase 3 randomised trial. Lancet Oncology 2015; 16: 990–8.
4 Yu HA, Arcila ME, Rekhtman N et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013; 19: 2240–7.
5 Jänne PA, Yang JC, Kim DW et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 2015; 372: 1689–99.
6 Zhang X, Yang J, Chen H et al. MET overexpression as a promising therapeutic target in non-small cell lung cancer with acquired resistance to EGFR TKIs. 2014 ASCO Annual Meeting Proceedings. J Clin Oncol 2014; 32 (15 Suppl.): e19047.
7 Chen ZY, Zhong WZ, Zhang XC et al. EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas. Oncologist 2012; 17: 978–85.
8 Yang JJ, Chen HJ, Yan HH et al. Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer. Lung Cancer 2013; 79: 33–9.